Epogin set for Japanese filing in chemotherapy setting
This article was originally published in Scrip
Executive Summary
Chugai (Roche) will file for the approval of its mainstay product Epogin (epoetin beta) for the additional indication of chemotherapy-induced anaemia in Japan by the end of this year.